RAD51 inhibition ameliorates secondary hyperparathyroidism: bioinformatic prediction and experimental verification

Scritto il 22/11/2026
da Xuemei Sun

Am J Transl Res. 2026 Oct 15;18(10):9251-9269. doi: 10.62347/JNCE1282. eCollection 2026.

ABSTRACT

Secondary hyperparathyroidism (SHPT) is a frequent complication of chronic kidney disease (CKD), and the transition of parathyroid hyperplasia from diffuse to nodular marks the shift from a pharmacologically manageable to a treatment-refractory state, yet the molecular basis of this transition remains unclear. We analyzed the GSE75886 dataset to compare differentially expressed genes from 8 nodular hyperplasia (NHD) and 5 diffuse hyperplasia (DHD) samples in SHPT. Key genes were screened by a combination of functional enrichment (GO/KEGG), protein-protein interaction network analysis, and ROC curve assessment. Meanwhile, a 5/6 nephrectomy (5/6 Nx) combined with a high-phosphorus diet rat model was established for in vivo validation experiments. While being fed a high-phosphorus diet, SHPT model rats received intraperitoneal injections of IBR2 (2 or 10 mg/kg) three times per week for four consecutive weeks; the cinacalcet group received cinacalcet (10 mg/kg) by oral gavage on the same schedule (three times per week for four weeks). After the treatment, parathyroid histomorphology, the Ki-67 positivity rate, serum biochemical parameters and the protein expression of RAD51, γH2AX, and cleaved caspase-3 were assessed. We identified 914 differentially expressed genes in our analysis. GO and KEGG enrichment linked these genes to DNA replication regulation, ferroptosis, and non-homologous end-joining. Protein-protein interaction network and topology analyses pinpointed eight hub genes (CTNNB1, ALB, BCL2, H3C13, H4C6, RAD51, IL10, and SOX2), with RAD51 achieving perfect discriminatory performance (AUC = 1.000). Among these, Rad51 was the most highly upregulated (5.87-fold) in the rat SHPT model and was therefore pursued for functional validation. Blocking RAD51 pharmacologically attenuated parathyroid hyperplasia (reducing Ki-67 from 20.62% to 3.03%), lowered circulating PTH, and reestablished normocalcemia. By contrast, cinacalcet lowered PTH but failed to normalize calcium concentrations. At the mechanistic level, RAD51 preserves DNA repair integrity (γH2AX accumulation signifies repair dysfunction) and constrains apoptosis; its inhibition unleashes cleaved-caspase-3-driven cell death, distinguishing it from cinacalcet's mode of action. RAD51 inhibition alleviates SHPT through impaired DNA repair and enhanced parathyroid cell apoptosis. These findings identify RAD51 as a novel therapeutic target for SHPT, with potential relevance to nodular hyperplasia.

PMID:43068086 | PMC:PMC13788506 | DOI:10.62347/JNCE1282